Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Glox Therapeutics, a company pioneering the development of precision antibiotics to combat antimicrobial resistance, has raised £4.3M in early-stage funding to develop effective targeted therapeutics against antibiotic-resistant gram-negative bacteria.

antibiotics © Shutterstock

Antimicrobial resistance (AMR) is a major public health crisis throughout the world. It is estimated that around 1.27 million people per year die as a result of AMR due to the therapeutic failure of available antibiotics.

By 2050, AMR is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion, and there is an urgent need to develop new effective antimicrobial therapeutics.

Glox Therapeutics is developing precision antibiotics by using engineered protein bacteriocins. These novel antimicrobials exhibit remarkable potency and specificity, enabling them to effectively and selectively target gram-negative pathogens that have already developed AMR.#

Read the full story on the University of Oxford website.

Similar stories

From Responsive to Deep Solidarity: Reframing Global Health Governance in an Interdependent World

A new paper co-authored by Oxford Global Health Co-Director Professor Caesar Atuire and Athanasius Afful from the University of Ghana explores how the concepts of deep solidarity and responsive solidarity can help reframe global health governance and address persistent inequities.

Inside the Medicine Quality Monitoring Globe: tracking medicine quality risks in real time

A new study sets the development and the process powering the Medicine Quality Monitoring Globe, the interactive, online tool that maps real-time medicine quality reports in the media. As of October 2026, the system has captured 2.5 million articles.

Adding rituximab to chemotherapy is a cost-effective treatment for Burkitt lymphoma in Tanzania

New research has found that adding rituximab to chemotherapy could be a cost-effective way to improve survival in children with Burkitt lymphoma in Tanzania.

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

Oxford researchers support international response to Bundibugyo virus disease outbreak

Teams from across the University of Oxford are supporting the international response to the current Bundibugyo virus disease outbreak through interdisciplinary research spanning biomedical, public health and social and behavioural science.

Smoking and drinking exacerbate social inequalities in premature deaths in India

Study finds social inequality is a major predictor of premature death, even among people who neither smoke nor drink alcohol.

Similar stories

From Responsive to Deep Solidarity: Reframing Global Health Governance in an Interdependent World

A new paper co-authored by Oxford Global Health Co-Director Professor Caesar Atuire and Athanasius Afful from the University of Ghana explores how the concepts of deep solidarity and responsive solidarity can help reframe global health governance and address persistent inequities.

Inside the Medicine Quality Monitoring Globe: tracking medicine quality risks in real time

A new study sets the development and the process powering the Medicine Quality Monitoring Globe, the interactive, online tool that maps real-time medicine quality reports in the media. As of October 2026, the system has captured 2.5 million articles.

Adding rituximab to chemotherapy is a cost-effective treatment for Burkitt lymphoma in Tanzania

New research has found that adding rituximab to chemotherapy could be a cost-effective way to improve survival in children with Burkitt lymphoma in Tanzania.

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

Oxford researchers support international response to Bundibugyo virus disease outbreak

Teams from across the University of Oxford are supporting the international response to the current Bundibugyo virus disease outbreak through interdisciplinary research spanning biomedical, public health and social and behavioural science.

Smoking and drinking exacerbate social inequalities in premature deaths in India

Study finds social inequality is a major predictor of premature death, even among people who neither smoke nor drink alcohol.